These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 22565972)

  • 1. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.
    Haynes BF; Kelsoe G; Harrison SC; Kepler TB
    Nat Biotechnol; 2012 May; 30(5):423-33. PubMed ID: 22565972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.
    LaBranche CC; Henderson R; Hsu A; Behrens S; Chen X; Zhou T; Wiehe K; Saunders KO; Alam SM; Bonsignori M; Borgnia MJ; Sattentau QJ; Eaton A; Greene K; Gao H; Liao HX; Williams WB; Peacock J; Tang H; Perez LG; Edwards RJ; Kepler TB; Korber BT; Kwong PD; Mascola JR; Acharya P; Haynes BF; Montefiori DC
    PLoS Pathog; 2019 Sep; 15(9):e1008026. PubMed ID: 31527908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.
    Bonsignori M; Montefiori DC; Wu X; Chen X; Hwang KK; Tsao CY; Kozink DM; Parks RJ; Tomaras GD; Crump JA; Kapiga SH; Sam NE; Kwong PD; Kepler TB; Liao HX; Mascola JR; Haynes BF
    J Virol; 2012 Apr; 86(8):4688-92. PubMed ID: 22301150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques.
    Yacoob C; Lange MD; Cohen K; Lathia K; Feng J; Glenn J; Carbonetti S; Oliver B; Vigdorovich V; Sather DN; Stamatatos L
    PLoS Pathog; 2018 Jun; 14(6):e1007120. PubMed ID: 29933399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV Broadly Neutralizing Antibodies: VRC01 and Beyond.
    Wu X
    Adv Exp Med Biol; 2018; 1075():53-72. PubMed ID: 30030789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design.
    Finney J; Kelsoe G
    Retrovirology; 2018 Jul; 15(1):53. PubMed ID: 30055635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
    Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
    Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
    Easterhoff D; Moody MA; Fera D; Cheng H; Ackerman M; Wiehe K; Saunders KO; Pollara J; Vandergrift N; Parks R; Kim J; Michael NL; O'Connell RJ; Excler JL; Robb ML; Vasan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Liao HX; Ferrari G; Seaman MS; Montefiori DC; Tomaras GD; Harrison SC; Haynes BF
    PLoS Pathog; 2017 Feb; 13(2):e1006182. PubMed ID: 28235027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody polyspecificity and neutralization of HIV-1: a hypothesis.
    Haynes BF; Moody MA; Verkoczy L; Kelsoe G; Alam SM
    Hum Antibodies; 2005; 14(3-4):59-67. PubMed ID: 16720975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.
    Jardine JG; Sok D; Julien JP; Briney B; Sarkar A; Liang CH; Scherer EA; Henry Dunand CJ; Adachi Y; Diwanji D; Hsueh J; Jones M; Kalyuzhniy O; Kubitz M; Spencer S; Pauthner M; Saye-Francisco KL; Sesterhenn F; Wilson PC; Galloway DM; Stanfield RL; Wilson IA; Burton DR; Schief WR
    PLoS Pathog; 2016 Aug; 12(8):e1005815. PubMed ID: 27560183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies.
    Hwang JK; Wang C; Du Z; Meyers RM; Kepler TB; Neuberg D; Kwong PD; Mascola JR; Joyce MG; Bonsignori M; Haynes BF; Yeap LS; Alt FW
    Proc Natl Acad Sci U S A; 2017 Aug; 114(32):8614-8619. PubMed ID: 28747530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
    Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
    J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
    Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
    Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.
    Banerjee S; Shi H; Banasik M; Moon H; Lees W; Qin Y; Harley A; Shepherd A; Cho MW
    Virology; 2017 May; 505():113-126. PubMed ID: 28237764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All eyes on the next generation of HIV vaccines: strategies for inducing a broadly neutralizing antibody response.
    Ahlers JD
    Discov Med; 2014 Apr; 17(94):187-99. PubMed ID: 24759623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
    Wu X; Yang ZY; Li Y; Hogerkorp CM; Schief WR; Seaman MS; Zhou T; Schmidt SD; Wu L; Xu L; Longo NS; McKee K; O'Dell S; Louder MK; Wycuff DL; Feng Y; Nason M; Doria-Rose N; Connors M; Kwong PD; Roederer M; Wyatt RT; Nabel GJ; Mascola JR
    Science; 2010 Aug; 329(5993):856-61. PubMed ID: 20616233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.